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Abstract 
This was a prospective study, to compare between body mass index (BMI) and waist hip ratio (WHR) in 
polycystic ovarian syndrome (PCOS). 120 PCOS patients, infertile and anovulatory, have been chosen. The 
mean age of the participating patients was ± 25 years ± 5.64 SD.  Measurements of WHR were taken by one 
person.   Body mass index was calculated in each patient using the formula BMI = weight (kg) / height (m2).  
On the second day of menstrual cycle, vaginal ultrasound was done for ovarian volume and microcysts 
numbers, and the following hormones were assayed: LH, FSH, oestradiol, prolactin, androstenedione, total 
testosterone, free testosterone and insulin. 72.5% of the studied PCOS patients their BMI were > 28 kg/m2, and 
82.5% their WHR were > 0.8. WHR correlated significantly with androstenedione (r = 0.271, P = 0.002), 
ovarian cyst number (r = 0.311, P = 0.000) and with the duration of infertility (r = 0.159, P = 0.044).  On the 
other hand, it was negatively correlated significantly with FSH (r = - 0.236, P = 0.005) and prolactin (r = - 182, 
P = 0.034). ).  BMI was positively correlated with prolactin level (r = - 0.195, p = 0.023).  There was no 
significant correlation between either BMI or WHR and serum levels of oestradiol (r = - 111, P = 0.205 and r = 
- 0.041, P = 0.641, respectively), insulin (r = 0.095, P = 0.275 and r = 0.035, P = 0.691, respectively), LH (r = 
0.074, P = 0.382 and r = 0.82, P = 0.328, respectively) and total testosterone (r = - 0.045, P = 0.61 and r = 
0.055, P 0.536, respectively) or free testosterone (r = - 0.021, P = 0.812 and r = 0.163, P = 0.061, respectively.  
Neither BMI nor WHR had significant correlation with the ovarian volume. But, the difference in WHR was 
significant between patients with ovarian volumes ≤ 9 ml and > 9 ml.   
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In addition, total testosterone level increased significantly in patients with WHR > 0.8.  This study indicated 
that WHR is a good mirror to the androgen levels and ovarian morphologies in PCOS patients. So, it is more 
reliable in reflecting the clinical features, endocrine profiles, ovarian characteristics and metabolic status of 
PCOS that are independent of BMI.    
Keywords: Anovulation; hyperandrogenism; hyperinsulinaemia; obesity; polycystic ovarian syndrome.  
1. Introduction  
Polycystic ovary syndrome (PCOS) is defined by the National Institutes of Health (NIH) in April 1990, as a 
disorder having: i) hyperandrogenism and/or hyperandrogenemia, ii) oligo-ovulation, and iii) exclusion of 
known disorders. Alternatively, in Rotterdam [1] PCOS is defined, after the exclusion of related disorders, by 
two of the following three features: i) oligo- or anovulation, ii) clinical and/or biochemical signs of 
hyperandrogenism, or iii) polycystic ovaries. In essence, the Rotterdam 2003 expanded the NIH 1990 definition 
creating two new phenotypes: a) ovulatory women with polycystic ovaries and hyperandrogenism, and b) oligo-
anovulatory women with polycystic ovaries, but without hyperandrogenism. 
To date, PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or 
PCO) is sufficient for clinical diagnosis.  Known disorders which mimic the PCOS phenotype should be 
excluded.  
Patients with PCOS have increased proportion of central to peripheral fat ratio; android pattern fat distribution. 
There is a positive correlation among trunkal fat and insulin [2].  Moreover, obesity impairs insulin resistance 
and exacerbates reproductive and metabolic features of PCOS.  The distribution of body fat has significant 
effects on different clinical, hormonal and metabolic features that are independent of body weight.  Increased 
WHRs are association with increased high levels of triglycerides and very low density lipoproteins, and lower 
levels of high density lipoproteins [3].  Obesity accentuates the metabolic alternations in PCOS, and is 
frequently an associated condition, either being an intrinsic component or a predisposing factor for the insulin 
resistance [4]. 
It has been reported that in obese PCOS patients, losing as little as 5 % of the initial body weight, improves 
spontaneous ovulation rates and spontaneous pregnancy. Weight reduction remains a worthwhile approach in 
obese women with PCOS [5, 6]. In this research, a comparison was made between body mass index and waist 
hip ratio in patients with PCOS. 
2. Patients and Methods 
2.1. Patients 
This study was done in OB/GYN department of Benha Teaching Hospital.  A total of 120 PCOS patients were 
selected. The mean age of the participating patients was ± 25 years ± 5.64 SD. Most of the patients (76.5%) 
their ages were between 20 and 30 years.  All the patients were seen because of infertility and diagnosed to have 
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PCOS. They had spontaneous onset of puberty and normal sexual development. 74 patients (70%) had primary 
infertility and 36 patients (30%) had secondary infertility. The mean duration of infertility was 3.8 years ± 2.7 
SD. 
The diagnosis of PCOS was based on the clinical diagnosis of PCOS and ultrasound evidences of polycystic 
ovary (PCO). The clinical diagnosis was based on the presence of at least two of the following criteria: oligo-
amenorrhoea, obesity (BMI ≥ 28), and clinical signs of hyperandrogenism or elevated either LH or LH/FSH 
ratio.  Ultrasound diagnosis of PCO was based on the presence of ≥ 5 microcysts distributed peripherally and 
the hyperechoic stromal density of both ovaries. 
2.2. Clinical Examination 
Each patient underwent a screening history and physical examination.  Measurements of waist to hip ratio were 
taken by one person. While standing up and relaxed, the smallest area around the waist using a measuring tape 
was taken (usually just above or around the umbilicus) and the circumference of hips (the widest diameter of the 
hips, usually at the levels of bony prominences or the level of greater trochanters of both femurs).   Body mass 
index (BMI) was calculated in each patient using the formula BMI = weight (kg) / height (m2).   
The menstrual cycle was described as being either regular, oligomenorrhoeic (a cycle interval of longer than 35 
days but less than 6 months) or amenorrhoeic (no menstruation for 6 months or more).  mean 
2.3. Ultrasound Examination 
All women had undergone transvaginal ultrasound, Medison, SonoaceR5. Ultrasound was done in the early 
follicular phase between the 2nd and 3rd day of the menstrual cycle. In amenorrhoeic women, the investigations 
were performed after progestogen induced withdrawal bleeding.   
The ovary was defined as being polycystic if there were multiple (more than four), small (2-8 mm) cysts 
arranged peripherally with increased echogenicity of the stroma.  In addition, the ovary was measured in three 
planes, then the ovarian volume was calculated according to the formula for a prolate ellipsoid: (d1) x (d2) x 
(d3) x 0.5233, where the d1, d2, d3 are the three maximal longitudinal, anteroposterior and transverse 
diameters.  Ovaries were considered enlarged when the ovarian volume exceeded 9 ml.  Ovaries containing 
cysts (a dominant follicle, simple cyst, haemorrhagic cyst, endometrioma, and corpus luteum) > 14 mm in 
diameter were excluded.  The number of small follicles in each ovary and the maximal diameter of follicle were 
also calculated carefully. The patients were divided into three groups ultrasonographically; group (I) (n = 36), in 
which less than 10 cysts were identified; group (II) (n = 48), in which there were between 10 and 14 cysts 
located under the ovarian capsule; group (III) (n = 36), in which more than 14 cysts were found under the 
ovarian capsule.   
2.4. Hormonal Measurements 
The following hormones were assayed on the second day of menses: LH, FSH, oestradiol, prolactin, 
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androstenedione, total testosterone, free testosterone and insulin.   
Serum FSH and LH were measured using an immunoradiometric assay (IRMA CT cat. KP6CT) on solid phase 
(coated tube) (RADIM S.p.A Via del Mare, Pomezia “Roma”- Italia).  The sensitivity was 0.18 and 0.20 
mIU/ml, respectively.  Serum 17β oestradiol was measured using radioimmunoassay (RIA) cat. KS25CT 
(RADIM S.p.A. Via del Mare, Pomezia “Roma”- Italia). The sensitivity was 10 pg/ml. 
Androstenedione was measured by radioimmunoassay using Coat-A-Count Direct Androstenedione procedure 
(Diagnostic Products Corporation, Los Angeles, CA, USA). The sensitivity was approximately 0.04 ng/ml (0.14 
nmol/L). Serum total testosterone was measured by radioimmunoassay (RIA) cat. KS24CT (RADIM S.p.A. Via 
del Mare, Pomezia “Roma”-Italia). The sensitivity was 0.017 ng/ml.  Free testosterone was measured by the 
DSL-4900 ACTIVETM  Free Testosterone Coated-Tube Radioimmunoassay Kit (Corporate Headquarters, 
Webster, Texas, USA). Sensitivity was 0.18 pg/ml. 
Serum insulin was measured by the DSL-1600 Insulin Radioimmunoassay Kit (Corporate Headquarters, 
Webster, Texas, USA). Sensitivity was 1.3 µIU/ml. 
Serum prolactin was measured by immunoradiometric assay (IRMA CT cat. KP8CT) on solid phase (coated 
tube) (RADIM S.p.A. Via del Mare, Pomezia “Roma”-Italia).  The sensitivity was 1 ng/ml (30 µIU/ml). All the 
results are expressed as mean.    
2.5. Statistics 
Analysis of data was performed using the Statistical Package for Social Sciences computer program 
(SPSS/PC+). The data were analyzed using the analysis of variance (ANOVA). Pearson’s product-moment 
coefficient r was also used to test the correlation between the endocrine and the biophysical data after log 
transformation. Analysis of variance after log transformation and chi-square was used in addition to t-Test and 
Z-Test, when appropriate, to test the differences between groups.  
3. Results 
3.1. Figures and Tables  
Most of the selected patients (87/120) (72.5%), their BMI were > 28 kg/m2, and (99/120) (82.5%) their WHR 
were > 0.8.  
There was no significant difference in the BMI between the groups of ovarian cysts or the sub-groups of the 
ovarian volume.  However, the difference in WHR was significant between the two subgroups of ovarian 
volume (t-test).  The WHR in the groups of the ovarian cysts, unlike BMI, was apparently increasing from 
group (I) to group (III) (Table 1).    
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Table 1: Differences between BMI and WHR patients depending on the ultrasound findings: 
 
Variable 
 
Ovarian cysts Ovarian volume 
Gr.I 
(<10) 
(n=36) 
Gr.II 
(10-14) 
(n=48) 
Gr.III 
(>14) 
(n=36) 
Subgr. 
≤ 9ml 
(n=42) 
Subgr. 
> 9ml 
(n=78) 
BMI 31.9 30.9 31.4 30.6 31.7 
WHR 0.84 0.86 0.89 0.851      0.861 + 
Gr. = Group (according to the number of microcysts in the ovary).  Subgr. = Subgroup (according to the ovarian 
volume).   (+) P < 0.05 between subgroups of the ovarian volume (t-test). 
 
Table 2: Hormonal differences between the BMI and WHR in the studied PCOS patients: 
 
Hormone  
WHR BMI 
≤ 0.8  
(n=21) 
> 0.8 
 (n=99) 
≤ 28 
(n=33) 
>28 
(n=87) 
LH 10.9 7.68 8.69 8.07 
FSH 5.53 4.89 4.59 5.16 
Estradiol 100.7 80.96 71.08 90.11 
Total testosterone 0.96 1.1      (+) 1.15 1.05 
Free testosterone 2.82 4.04    (a) 3.69 3.71 
Androstenedione 2.9 3.95 3.44 3.43 
Prolactin 443.6 314.5 446.6 295.6 
Insulin 7.8 13.5 10.5 12.9 
N.B.:  (+) P<0.05, (a) P = 0.081 Comparing values between corresponding subgroup (t-Test). 
There were no significant differences in the hormonal levels between the patients of BMI ≤ 28 and > 28.  On the 
other hand, the differences were obvious between the patients depending on WHR (Table 2). Total testosterone 
was significantly higher in patients with WHR > 0.8.  The LH level was higher, and the androgens levels and 
insulin levels are lower in patients with WHR ≤ 0.8 than in patients with WHR > 0.8.  
There was no significant correlation between the menstrual patterns of PCOS patients and WHR or BMI. 
However, BMI were apparently less in the patients with normal menses than in patients with amenorrhoea or 
oligomenorrhoea (Table 3).  
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Table 3: Differences between BMI and WHR depending on the menstrual presentation in PCOS patients: 
 Variable PCOS  patients 
Amenorrhea 
(n=42) 
Oligomenorrhoea 
(n=63) 
Regular 
(n=15) 
BMI 32.3 32 28.1 
WHR 0.87 0.85 0.89 
 
3.2. Correlations 
Neither BMI nor WHR had significant correlation with ovarian volume. However, only WHR was significantly 
correlated with ovarian cyst number (r = 0.311, P = 0.000), androstenedione (r = 0.271, P = 0.002), and with the 
duration of infertility (r = 0.159, P = 0.044). On the other hand, WHR was negatively correlated significantly 
with FSH (r = - 0.236, P = 0.005) and prolactin (r = - 182, P = 0.034). There was no significant correlation 
between either BMI or WHR and serum levels of oestradiol (r = - 111, P = 0.205 and r = - 0.041, P = 0.641, 
respectively), insulin (r = 0.095, P = 0.275 and r = 0.035, P = 0.691, respectively), LH (r = 0.074, P = 0.382 and 
r = 0.82, P = 0.328, respectively) and total testosterone (r = - 0.045, P = 0.61 and r = 0.055, P 0.536, 
respectively) or free testosterone (r = - 0.021, P = 0.812 and r = 0.163, P = 0.061, respectively).  Only, BMI was 
correlated with prolactin level (r = - 0.195, p = 0.023).  FSH was negatively correlated significantly with the 
WHR (r = 0.236, P = 0.005).   
4. Discussion 
In this research, WHR was significantly correlated positively with ASD, ovarian cyst numbers, duration of 
infertility and negatively with FSH and prolactin.  Also, the difference in WHR was significant between patients 
with ovarian volumes ≤ 9 ml and > 9 ml.  In addition, total testosterone level was significantly higher in PCOS 
patients with WHR > 8.  Moreover, there were obvious increases of free testosterone, ASD and insulin levels in 
PCOS patients with WHR >8. Our findings are supporting the android pattern of fat distributions in those 
patients with WHR > 0.8 and the reliability of WHR in reflecting the clinical, hormonal and metabolic features 
of PCOS that are independent of body weight.   
On the other hand, and apart from grouping and subgrouping systems of the ultrasound findings, there was no 
significant correlation between WHR or BMI and ovarian volume, oestradiol, insulin, LH and total and free (T).  
The authors in [3] have reported that increased WHRs were associated with increased LH and ASD 
concentrations.  Abdel Gadir and his collegues [7] did not find significant correlation between BMI and FSH, 
oestradiol, T, prolactin and ovarian volume.  In another study done by the authors in [8], no relationship could 
be established between BMI and follicle number, ovarian volume and testosterone.  
The authors in [9, 10] have another opinion that the number of follicles per ovary have been correlated 
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positively with BMI.  In addition, BMI had significant correlation with the ovarian volume and testosterone 
concentration [11], free testosterone [12, 13] and with insulin levels [13].    In another research [9], the ovarian 
volume was positively correlated with BMI and WHR.   However, increase BMI was not always associated 
with high glucose and insulin levels while high WHR tended to be so [14].  In this research, the insulin levels 
were higher in those patients with BMI >28 and WHR > 0.08 than in their counterparts. Although the relations 
were not significant, it may support the common view of the positive relationship between obesity and 
hyperinsulinaemia. Obese PCOS patents have significantly higher WHR than reference subjects with similar 
BMI, and are related positively with their insulin levels, whereas the WHR of non-obese PCOS and reference 
subjects are not different [14].   
The authors in [7, 15] have shown a negative association between BMI and LH.    In this research, in spite of 
the relation was not significant, the levels of LH in patients with WHR ≤ 0.8 were higher than in patient with 
WHR > 0.8. This may suggest possible different etiology and pathogenesis between the two sub-groups.  
Our findings, supported by other literatures [7, 8, 14], may suggest the limitation of BMI in reflecting the 
metabolism of PCOS women, and the potential usefulness of the WHR.   
5. Conclusion 
It is better to include WHR in addition to the BMI as routine measurements in PCOS patients. WHR is a good 
mirror to the androgen levels and ovarian morphologies in PCOS patients. So, it is more reliable than BMI in 
reflecting the clinical features, endocrine profiles, ovarian characteristics and metabolic status in PCOS.     
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